v3.26.1
Revenue - Allocation of Performance Obligation (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Collaboration License And Funding Arrangements [Line Items]        
Revenue from external customers $ 8,806 $ 1,973 $ 11,514 $ 30,780
Norgine Agreement        
Collaboration License And Funding Arrangements [Line Items]        
Remaining performance obligation 35,534   35,534  
Revenue from collaborative arrangement, excluding revenue from contract with customer     5,509 28,094
Norgine Agreement, License        
Collaboration License And Funding Arrangements [Line Items]        
Remaining performance obligation 33,096   33,096  
Revenue from collaborative arrangement, excluding revenue from contract with customer     5,457 27,639
Norgine Agreement, R&D - WHIM        
Collaboration License And Funding Arrangements [Line Items]        
Remaining performance obligation 373   373  
Revenue from collaborative arrangement, excluding revenue from contract with customer     5 25
Norgine Agreement, R&D - CN        
Collaboration License And Funding Arrangements [Line Items]        
Remaining performance obligation $ 2,065   2,065  
Revenue from collaborative arrangement, excluding revenue from contract with customer     47 430
Norgine Agreement, Drug Product Supply        
Collaboration License And Funding Arrangements [Line Items]        
Revenue from collaborative arrangement, excluding revenue from contract with customer     1,163 0
Norgine Agreement License and Other Revenue        
Collaboration License And Funding Arrangements [Line Items]        
Revenue from collaborative arrangement, excluding revenue from contract with customer     $ 6,672 $ 28,094